Karen L. Smith
CIK 1639637 · Chief Medical Officer · last filed 2026-04-02
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$7.06M
Companies
12
Total Filings
54
Lifetime Open-Market Net
-$2.68M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SKYE | Director | — | $0.79 | — | $0 | 5 | 2026-04-02 |
| SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Director | 102,100 | $0.18 | $18.1K | $0 | 9 | 2025-06-16 |
| CNTX | Director | — | $1.39 | — | $0 | 2 | 2025-06-12 |
| AUPH | Director | 24,807 | $15.82 | $392.4K | -$44.2K | 3 | 2024-11-25 |
| Tourmaline Bio, Inc. (TALS) Delisted | Director | — | $27.20 | — | $0 | 3 | 2023-06-14 |
| QNCX | Chief Medical Officer | — | $0.93 | — | $0 | 1 | 2023-02-02 |
| Quince Therapeutics, Inc. (CRTX) Delisted | Chief Medical Officer | 194,690 | $1.95 | $379.6K | $0 | 2 | 2022-05-27 |
| ACCELERON PHARMA INC (XLRN) Delisted | Director | 0 | $178.75 | $0 | -$2.88M | 8 | 2021-11-22 |
| ANTARES PHARMA, INC. (ATRS) Delisted | Director | 79,645 | $5.59 | $445.2K | $0 | 4 | 2021-06-14 |
| EBS | EVP, Chief Medical Officer | 11,888 | $8.32 | $98.9K | $0 | 2 | 2021-05-11 |
| JAZZ | EVP, R&D and CMO | 28,474 | $230.56 | $6.56M | $250.0K | 13 | 2018-03-07 |
| Sucampo Pharmaceuticals, Inc. (SCMP) Delisted | Director | — | — | — | $0 | 1 | 2018-02-13 |
Recent Filings · Page 3 of 6
54 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-03-01 | SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Grant (A) | +12,500 | $0 | EDGAR |
| 2021-11-22 | ACCELERON PHARMA INC (XLRN) Delisted | Mixed | −1,622 | $0 | EDGAR |
| 2021-06-14 | ANTARES PHARMA, INC. (ATRS) Delisted | Grant (A) | +25,452 | $112.5K | EDGAR |
| 2021-05-11 | EBS | Tax (F) | −305 | -$18.6K | EDGAR |
| 2021-04-05 | ACCELERON PHARMA INC (XLRN) Delisted | Mixed | −2,939 | -$1.30M | EDGAR |
| 2021-04-02 | ACCELERON PHARMA INC (XLRN) Delisted | Mixed | — | -$854.6K | EDGAR |
| 2021-03-01 | SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Grant (A) | +8,200 | $0 | EDGAR |
| 2021-02-26 | EBS | Grant (A) | +5,883 | $0 | EDGAR |
| 2021-02-02 | ACCELERON PHARMA INC (XLRN) Delisted | Grant (A) | +1,622 | $0 | EDGAR |
| 2020-06-15 | ANTARES PHARMA, INC. (ATRS) Delisted | Grant (A) | +30,220 | $82.5K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.